Abemaciclib Cas:1231929-97-7
Abesili is a CDK4/6 inhibitor that is activated by binding to cyclin D. In estrogen receptor-positive (ER+) breast cancer cell lines, cyclin D1 and CDK4 and 6 promote retinoblastoma protein (Rb) phosphorylation, accelerating cell cycle progression and cell proliferation.
Intro
Abesilide is an oral cyclin-dependent kinase CDK4/6 inhibitor. In HR+, HER2-breast cancer cells, CDK4 and CDK6 promote the phosphorylation of retinoblastoma protein (Rb) and promote cell cycle progression and cell proliferation. Abemaciclib inhibits the phosphorylation of Rb and blocks the progression of cells from the G1 phase of the cell cycle to the S phase, leading to cell senescence and apoptosis.
Indication
Abesilide in combination with fulvestrant for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer. Verzenio alone is used to treat the same group of patients whose cancer has metastasized after endocrine therapy and chemotherapy.
